BC Extra | Jul 8, 2019
Clinical News

July 8 Clinical Quick Takes: Hemophilia data from Sangamo-Pfizer, Novo; plus GamaMabs, Xarelto and more

Sustained Factor VIII levels for Sangamo, Pfizer hemophilia A gene therapy  Sangamo Therapeutics Inc. (NASDAQ:SGMO) and partner Pfizer Inc. (NYSE:PFE) presented data at the International Society on Thrombosis and Haemostasis (ISTH) meeting in Melbourne showing...
BioCentury | Jun 2, 2018
Product Development

Breaking from the herd

Behind the block of clinical studies on PD-1 and PD-L1 inhibitors, researchers are casting aside their herd mentality with a wide net of strategies to solve some of the most pressing problems in oncology, such...
BC Week In Review | Jun 1, 2018
Clinical News

GamaMabs reports Phase I data for GM102 in gynecological cancers

GamaMabs Pharma S.A. (Toulouse, France) reported data from four evaluable patients with granulosa ovarian cancer in the Phase Ia/Ib C101 trial showing that GM102 led to two partial responses. GM102 was well tolerated with no...
BC Innovations | May 23, 2018
Distillery Techniques

Disease models

TECHNOLOGY: Animal models Mice treated prenatally with AMH could be used to screen therapies to treat polycystic ovary syndrome, a partially heritable disease. In blood samples from 66 pregnant patients with PCOS, AMH levels were...
BC Innovations | May 11, 2017
Tools & Techniques

Stemming the tide

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...
BC Innovations | Mar 8, 2017
Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Infertility Mouse studies suggest an engineered version of AMH could help prevent infertility in women receiving chemotherapy. Native AMH was engineered with sequence alterations that enhanced the rate of a specific proteolytic cleavage reaction...
BC Innovations | Mar 2, 2017
Targets & Mechanisms

Fertile testing ground

Research from Massachusetts General Hospital suggests the sex differentiation hormone AMH could be used to protect egg reserves in female cancer patients by keeping ovarian follicles quiet during chemotherapy. The scientists behind the work have...
BioCentury | Nov 5, 2016

Vive la biotech

The French biotech sector has historically lagged other European countries such as the U.K. and Germany in both financings and deals. But a fledgling group of public bellwethers and a crop of innovative private companies...
BC Week In Review | Aug 8, 2016
Clinical News

GM102: Phase Ia/Ib started

GamaMabs began an open-label, dose-escalation, European Phase Ia/Ib trial to evaluate IV GM102 in previously treated patients with advanced, AMHR2-positive gynecological tumors. The dose-escalation Phase Ia portion will enroll 18 patients to identify a dose...
BC Extra | Dec 15, 2015
Financial News

GamaMabs raises EUR 15M in series B

GamaMabs Pharma S.A. (Tolouse, France) raised EUR 15 million ($16.4 million) in a series B round led by new investor Edmond de Rothschild Investment Partners (EdRIP) via its BioDiscovery 4 fund. Existing investors InnoBio, Irdinov,...
Items per page:
1 - 10 of 18